Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALSSOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

Biogen Inc. announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.